Find Molsidomine manufacturers, exporters & distributors on PharmaCompass

Alpharma Brand Of Molsidomine

Alpharma Brand of Molsidomine

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

3 API Suppliers, 1 CEP/COS, 1 KDMF, 2 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports, API Imports

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

1,285

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 25717-80-0, Morsydomine, Corvaton, Motazomin, Molsidolat, Sin-10

Molecular Formula

C₉H₁₄N₄O₄

Molecular Weight

242.23 g/mol

InChI Key

XLFWDASMENKTKL-UHFFFAOYSA-N

FDA UNII

D46583G77X

A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.

1 2D Structure

Alpharma Brand of Molsidomine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(1E)-1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate

2.1.2 InChI

InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3

2.1.3 InChI Key

XLFWDASMENKTKL-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCOC(=NC1=C[N+](=NO1)N2CCOCC2)[O-]

2.1.5 Isomeric SMILES

CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-]

2.2 Other Identifiers

2.2.1 UNII

D46583G77X

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Corpea

2. Corvaton

3. Duracoron

4. Fali Cor

5. Fali-cor

6. Heumann, Molsidomin

7. Korvatone

8. Molsi 1a Pharma

9. Molsi Azu

10. Molsi Puren

11. Molsi-azu

12. Molsi-puren

13. Molsibeta

14. Molsicor

15. Molsidain

16. Molsidomin

17. Molsidomin Heumann

18. Molsidomin Ratiopharm

19. Molsidomin Stada

20. Molsidomin Von Ct

21. Molsidomin-ratiopharm

22. Molsihexal

23. Molsiket

24. Morsydomine

25. Mtw Molsidomin

26. Mtw-molsidomin

27. Sin 10

28. Sin-10

29. Sin10

30. Sydnopharm

31. Von Ct, Molsidomin

2.3.2 Depositor-Supplied Synonyms

1. 25717-80-0

2. Morsydomine

3. Corvaton

4. Motazomin

5. Molsidolat

6. Sin-10

7. Morial

8. N-ethoxycarbonyl-3-morpholinosydnonimine

9. Cas 276

10. Mls000028573

11. Sydnone Imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)-

12. N-carboxy-3-morpholinosydnone Imine Ethyl Ester

13. (1e)-1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate

14. Smr000058990

15. Sydnopharm

16. Cas-276

17. D46583g77x

18. Nsc-757398

19. N-carboxy-3-morpholinosydnonimine Ethyl Ester

20. Ncgc00015661-02

21. Cas-25717-80-0

22. N-(ethoxycarbonyl)-3-(4-morpholinyl)sydnone Imine

23. N-[3-(4-morpholinyl)-5-oxadiazol-3-iumyl]carbamic Acid Ethyl Ester

24. Sydnone Imine, N-carboxy-3-morpholino-, Ethyl Ester

25. Dsstox_cid_25171

26. Dsstox_rid_80721

27. Dsstox_gsid_45171

28. Molsidomina

29. Molsidominum

30. Covarsal

31. Molsidominum [inn-latin]

32. Molsidomina [inn-spanish]

33. Sr-05000001464

34. Einecs 247-207-4

35. Brn 3999414

36. Unii-d46583g77x

37. Ethyl (nz)-n-(3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-ylidene)carbamate

38. Molsidomine [usan:inn:ban:jan]

39. N-(ethoxycarbonyl)-3-(4-morpholino)sydnone Imine

40. Prestwick_863

41. Mfcd00869301

42. Opera_id_238

43. Molsidomine [mi]

44. Prestwick3_000547

45. Lopac-m-2901

46. Molsidomine [inn]

47. Molsidomine [jan]

48. Molsidomine [usan]

49. Molsidomine [mart.]

50. Schembl34019

51. Bspbio_000593

52. Molsidomine [who-dd]

53. Mls001146942

54. Mls002153869

55. Spectrum1500673

56. Molsidomine (jan/usan/inn)

57. Bpbio1_000653

58. Chembl1256353

59. Chembl1329455

60. Chembl4059924

61. Dtxsid0045171

62. Bdbm39912

63. Chebi:92623

64. Cid_5353788

65. Hms501o05

66. Hms1569n15

67. Hms1921a16

68. Hms2089l03

69. Hms2092g20

70. Hms2096n15

71. Hms2232f20

72. Hms2235b12

73. Hms3262a12

74. Hms3649m16

75. Hms3713n15

76. Molsidomine [ep Monograph]

77. Hy-b1069

78. Molsidomine 1.0 Mg/ml In Methanol

79. Tox21_110192

80. Tox21_500725

81. Bdbm50248123

82. Ccg-40069

83. S4664

84. Akos015843340

85. Akos015900360

86. Akos015962928

87. Akos026749793

88. Tox21_110192_1

89. Ac-7473

90. Ccg-220547

91. Cs-4625

92. Db09282

93. Ks-5160

94. Nsc 757398

95. Sdccgsbi-0050703.p005

96. Ncgc00015661-01

97. Ncgc00015661-03

98. Ncgc00015661-04

99. Ncgc00015661-05

100. Ncgc00015661-06

101. Ncgc00015661-07

102. Ncgc00015661-08

103. Ncgc00015661-09

104. Ncgc00015661-10

105. Ncgc00015661-12

106. Ncgc00015661-16

107. Ncgc00024136-03

108. Ncgc00024136-04

109. Ncgc00024136-05

110. Ncgc00024136-06

111. Ncgc00024136-07

112. Ncgc00261410-01

113. Smr001233224

114. Sbi-0050703.p004

115. Ab00513859

116. Eu-0100725

117. D01320

118. Ab00052152_14

119. Ab00513859-02

120. A817988

121. Sr-05000001464-1

122. Sr-05000001464-3

123. W-107222

124. (1e)-1-ethoxy-n-(3-morpholinooxadiazol-3-ium-5-yl)formimidate

125. (ethoxycarbonyl)(3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide

126. 1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate

127. (1e)-1-ethoxy-n-[3-(4-morpholinyl)-5-oxadiazol-3-iumyl]methanimidate

128. (1e)-1-ethoxy-n-(3-morpholin-4-yl-1,2,3-oxadiazol-3-ium-5-yl)methanimidate

129. (1e)-1-ethoxy-n-(3-morpholinooxadiazol-3-ium-5-yl)methanimidate;molsidomine

2.4 Create Date

2005-03-25

3 Chemical and Physical Properties

Molecular Formula	C₉H₁₄N₄O₄
Molecular Weight	242.23 g/mol
XLogP3	2.2
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	4
Exact Mass	242.10150494 g/mol
Monoisotopic Mass	242.10150494 g/mol
Topological Polar Surface Area	87 Å²
Heavy Atom Count	17
Formal Charge	0
Complexity	270
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

The indications for use of molsidomine include ischemic heart disease, angina, chronic heart failure, and pulmonary hypertension.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Molsidomine leads to smooth muscle relaxation in the coronary blood vessels, relieving symptoms of angina and increasing blood flow to the coronary arteries.

5.2 MeSH Pharmacological Classification

Vasodilator Agents

Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)

Nitric Oxide Donors

A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81) (See all compounds classified as Nitric Oxide Donors.)

5.3 ATC Code

C - Cardiovascular system

C01 - Cardiac therapy

C01D - Vasodilators used in cardiac diseases

C01DX - Other vasodilators used in cardiac diseases

C01DX12 - Molsidomine

5.4 Absorption, Distribution and Excretion

Absorption

Peak plasma drug concentration (tmax) occurs from 1 to 2 hours after administration.

Volume of Distribution

98 L

Clearance

renal excretion is the main route of elimination of the metabolites in humans (90% to 95%) About 2% of the ingested drug is excreted unchanged in the urine.

5.5 Metabolism/Metabolites

Molsidomine hepatically metabolized to _linsidomine_. Linsidomine releases nitric oxide (NO) from endothelial cells when it decays, and acts as the active vasodilating metabolite responsible for molsidomine's pharmacological effects. Oral absorption of Molsidomine is found to be 95.5% 4.5. Presystemic metabolism is noted to be 56% and metabolism is reported extensive by Liver. Renal Excretion accounts for 95 % and plasma half-life is 5 hr. Back to top

5.6 Mechanism of Action

Molsidomine, a cardiovascular drug, acts in a similar fashion to organic nitrates. The SIN-1A metabolite of molsidomine has a pharmacologically active group of nitric oxide, which increases levels of cyclic GMP, and decreases intracellular calcium ions in smooth muscle cells. This leads to relaxation of smooth muscle in the blood vessels, and inhibits platelet aggregation.